ARMATA PHARMACEUTICALS, INC. (ARMP) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | Payments of Dividends |
| Net income · 12 months | -192.18M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-192.18M | (m) |
| 2026-03-31 | (m) | $-282.61M | (m) |
| 2025-12-31 | (m) | $-173.80M | (m) |
| 2025-09-30 | (m) | $-46.90M | (m) |
| 2025-06-30 | (m) | $-25.71M | (m) |
| 2025-03-31 | (m) | $-426.00K | (m) |
| 2024-12-31 | (m) | $-18.92M | (m) |
| 2024-09-30 | (m) | $-41.36M | (m) |
| 2024-06-30 | (m) | $-67.04M | (m) |
| 2024-03-31 | (m) | $-79.58M | (m) |
| 2023-12-31 | (m) | $-69.05M | (m) |
| 2023-09-30 | (m) | $-59.51M | (m) |
| 2023-06-30 | (m) | $-36.97M | (m) |
| 2023-03-31 | (m) | $-42.63M | (m) |
| 2022-12-31 | (m) | $-36.92M | (m) |
| 2022-09-30 | (m) | $-32.65M | (m) |
| 2022-06-30 | (m) | $-29.45M | (m) |
| 2022-03-31 | (m) | $-26.43M | (m) |
| 2021-12-31 | (m) | $-23.16M | (m) |
| 2021-09-30 | (m) | $-23.73M | (m) |
| 2021-06-30 | (m) | $-24.08M | (m) |
| 2021-03-31 | (m) | $-22.60M | (m) |
| 2020-12-31 | (m) | $-22.18M | (m) |
| 2020-09-30 | (m) | $-20.14M | (m) |
| 2020-06-30 | (m) | $-21.33M | (m) |
| 2020-03-31 | (m) | $-20.82M | (m) |
| 2019-12-31 | (m) | $-19.48M | (m) |
| 2019-09-30 | (m) | $-11.40M | (m) |
| 2019-06-30 | (m) | $-7.22M | (m) |
| 2019-03-31 | (m) | $-12.59M | (m) |
| 2018-12-31 | (m) | $-12.11M | (m) |
| 2018-09-30 | (m) | $-10.14M | (m) |
| 2018-06-30 | (m) | $-9.31M | (m) |
| 2018-03-31 | (m) | $-12.73M | (m) |
| 2017-12-31 | (m) | $-12.84M | (m) |
| 2017-09-30 | (m) | $-19.99M | (m) |
| 2017-06-30 | (m) | $-21.58M | (m) |
| 2017-03-31 | (m) | $-18.97M | (m) |
| 2016-12-31 | $80.00K | $-18.84M | -0.42% |
| 2016-09-30 | (m) | $-11.57M | (m) |
| 2016-06-30 | (m) | $-3.75M | (m) |
| 2016-03-31 | (m) | $10.87M | (m) |
| 2015-12-31 | (m) | $-516.00K | (m) |
| 2015-09-30 | (m) | $1.05M | (m) |
| 2015-06-30 | (m) | $16.82M | (m) |
| 2015-03-31 | (m) | $19.92M | (m) |
| 2014-12-31 | (m) | $23.11M | (m) |
| 2014-09-30 | (m) | $23.45M | (m) |
| 2014-06-30 | (m) | $-39.84M | (m) |
| 2014-03-31 | (m) | $-64.39M | (m) |
| 2013-12-31 | (m) | $-55.86M | (m) |
| 2013-09-30 | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |